Background. Reduced kidney function is a common public health problem that increases risk for a wide variety of adverse outcomes, making the identification of potentially modifiable factors associated with the development of incident chronic kidney disease (CKD) important. Alterations in the hypothalamicpituitary-thyroid axis have been linked to reduced kidney function, but the association of thyroid function with the development of incident CKD is largely uncharacterized. Methods. Concentrations of thyroid stimulating hormone (TSH), free thyroxine (FT4), triiodothyronine (T3) and thyroid peroxidase antibody (TPOAb) were quantified in 12 785 black and white participants of the ongoing community-based prospective Atherosclerosis Risk in Communities study. Thyroid markers and clinical categories of thyroid dysfunction (euthyroidism, combined subclinical and overt hypothyroidism, combined subclinical and overt hyperthyroidism) were also evaluated for their association with reduced kidney function (estimated glomerular filtration rate <60 mL/min/1.73 m
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Conclusions. Elevated TSH, FT4 and reduced T3 concentrations were associated with reduced kidney function crosssectionally. The lack of association with the development of incident CKD suggests that altered thyroid function in the general population is not causally related to CKD development, but screening for thyroidal status may be especially relevant in persons with reduced kidney function.
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I N T R O D U C T I O N
Approximately 13% of individuals in the general US population have chronic kidney disease (CKD), and the incidence is increasing globally [1] [2] [3] [4] . CKD is defined by the sustained presence of reduced kidney function or damage [5] , often resulting from diabetes mellitus (DM) and hypertension [6] . Treatment of CKD risk factors does not fully prevent the decline in renal function, suggesting that there may be additional unidentified risk factors.
Several lines of evidence connect the functions of the thyroid and kidneys, and alterations in the hypothalamic-pituitary-thyroid axis have been linked to reduced kidney function. Subclinical and overt hypothyroidism have been associated with adverse blood lipid alterations [7] , endothelial dysfunction [8] and accelerated atherosclerosis [9] , resulting in increased cardiovascular risk [10, 11] , the leading cause of death in CKD. The prevalence of hormonal derangements of thyroid stimulating hormone (TSH) and/or free thyroxine (FT4) increases from 5 up to 14% with the worsening of kidney function [12] . Low
triiodothyronine (T3) concentrations are found in up 75% of patients with advanced CKD (Stages G4-5) [13] .
So far, little is known about the association of a full panel of thyroid markers-TSH, FT4, T3 and TPOAb concentrations-with baseline kidney function or incident CKD. This is especially true for T3, which has not been measured in many epidemiological studies. Furthermore, the association of clinical categories of thyroid dysfunction with incident CKD is largely uncharacterized for a middle-aged cohort of Caucasian and African American origin and has so far only been studied by Zhang et al. [14] and Meuwese et al. [15] looking at an Asian population and a cohort of elderly participants, respectively.
The aim of our study was to investigate the cross-sectional and prospective associations of a full panel of thyroid markers as well as clinical categories of thyroid dysfunction with reduced kidney function in the Atherosclerosis Risk in Communities (ARIC) study, a large predominantly biracial prospective study of middle-aged adults.
M A T E R I A L S A N D M E T H O D S

Study population
The ARIC study is an ongoing community-based prospective cohort of 15 792 adults recruited from four US communities (Minneapolis, MN; Washington County, MD; Forsyth County, NC; Jackson, MS) ages 45-64 years at the baseline visit (1987-89). The ARIC study design and objectives have been fully described elsewhere [16] . In short, four visits every 3 years were conducted between 1987 and 1998; a fifth visit was conducted during 2011-13. Thyroid markers were measured in participants attending visit 2 (1990-92), the baseline visit for this study. Of the 13 500 participants attending ARIC visit 2, we excluded for this report the small groups reporting race other than black or white (n ¼ 40) as well as blacks from centers other than Jackson, MS or Forsyth County, NC (Minnesota: n ¼ 18; Maryland: n ¼ 30). We additionally excluded 110 participants missing thyroid parameters and 517 participants with missing information on one or more covariates [age, gender, center, race, serum albumin, body mass index (BMI), high-sensitivity C-reactive protein (hs-CRP), smoking status, estimated glomerular filtration rate (eGFR), systolic blood pressure, DM, lowdensity lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides, hypertension, and medication use for cholesterol and/or DM].
The study sample for the analyses of the prevalence of thyroid dysfunction at baseline thus consisted of 12 785 participants (9690 whites; 3095 blacks). Cross-sectional association analyses were conducted after excluding 676 participants taking any thyroid medication at baseline (leaving 12 109 overall; 9148 whites, 2961 blacks). For prospective analyses, participants with reduced kidney function (eGFR <60 mL/min/1.73 m 2 ) at visit 2 were additionally excluded (leaving 11 872 overall; 8996 whites, 2876 blacks). A sensitivity analysis was performed crosssectionally and prospectively, keeping all 676 participants taking thyroid medication at baseline.
Measurement of thyroid markers and definition of thyroid disease
Thyroid parameters [thyrotropin (TSH), free thyroxine (FT4), total triiodothyronine (T3) and TPO antibodies (TPOAb)] were assayed in 2012-13 for all participants from stored serum samples available from the second (1990-92) ARIC visit. All samples had been stored since collection at À70 C in monitored freezers at the University of Minnesota. Assays from Roche Diagnostics (Indianapolis, IN, USA) were implemented on an Elecsys 2010 analyzer. For FT4 detection, an indirect two-step competitive electrochemiluminescence immunoassay method was used. All interassay coefficients of variation (CVs) were 10% (Supplementary data, Table S1 ). Reference values for TSH, FT4 and T3 in ARIC were derived from their distributions in a healthy subset of ARIC participants (n ¼ 7394) as described previously [17] . Reference intervals for the race-specific analyses were established using the racespecific 2.5th and 97.5th percentiles for thyroid hormone measurements [18] . Percentiles of the distributions of thyroid function makers are found in Supplementary data, Table S2 . The derived reference ranges were 0.56-5.1 mIU/L for TSH (0.61-5.4 for whites and 0.47-4.2 for blacks), 10.9-18.0 pmol/L for FT4 (11.2-19 .3 for whites and 10.6-18.0 for blacks) and 1.4-2.6 nmol/L for T3 (1.4-2.6 for whites and 1.4-2.7 for blacks). TPOAb positivity was assumed for values >34 IU/mL as recommended by the manufacturer (Roche Diagnostics).
Euthyroidism was defined as both TSH and FT4 concentrations in the reference range, with all other participants considered noneuthyroid. Hypothyrodism included both subclinical and overt hypothyroidism. Subclinical hypothyroidism was defined as serum TSH concentrations above the reference range of >5.1 mIU/L (for race-specific analyses: whites, TSH >5.4 mIU/L; blacks, TSH >4.2 mIU/L), but FT4 concentrations within the reference range of 10.9-18.0 pmol/L (for racespecific analyses: whites, 11.2-19.3 pmol/L; blacks, 10.6-18.0 pmol/L). Overt hypothyroidism was defined as TSH concentrations above and FT4 below the established reference range of 10.9 pmol/L (for race-specific analyses: whites, <11.2 pmol/L; blacks, <10.6 pmol/L) [19] . Likewise, hyperthyroidism included subclinical and overt hyperthyroidism. Subclinical hyperthyroidism was defined as TSH concentrations below the reference range but FT4 concentrations within the reference range, and overt hyperthyroidism as TSH concentrations below and FT4 above the reference range. Medication data files from study visit 2 were used to evaluate the intake of thyroid medication for treated hypothyroidism [thyroid replacement medication: T4 supplements (n ¼ 633), T3 supplements (n ¼ 3) and T3/T4 supplements (n ¼ 35)] or treated hyperthyroidism (methimazole, propylthiouracil).
Measures of renal function and definitionof incident CKD
Creatinine was measured from serum (visit 2) and plasma (visit 4) by the modified kinetic Jaffé method [20] . To account for variability among laboratories, assays and methods, creatinine values were calibrated to the National Institute of Standards and Technology (NIST) standard [21] . GFR was estimated using the 2009 Chronic Kidney Disease Epidemiology Collaboration equation [22] and reduced kidney function was defined as eGFR <60 mL/min/1.73 m 2 , corresponding to Stage G3-5 CKD. Information on albuminuria, the other measure to define and stage CKD, was not available from ARIC visit 2.
Incident CKD for those without reduced kidney function at visit 2 (eGFR !60 mL/min/1.73 m 2 ) was defined by a combination of visit-based information (N ¼ 690 events) and hospitalization-based information (N ¼ 1313 events) as eGFR <60 mL/min/1.73 m 2 after visit 2 and an eGFR decline from baseline of !25%, as well as all US Renal Data System-identified ESRD events, and those with hospitalizations or deaths with CKD-related International Classification of Diseases, Ninth
Revision, Clinical Modification/International Classification of Diseases, Tenth Revision codes in any position as described previously [23] .
Covariates
Diabetes was defined as a self-reported physician diagnosis of disease, use of hypoglycemic medication, fasting glucose concentration !126 mg/dL or random glucose concentration !200 mg/ dL. Hypertension was defined as mean systolic blood pressure !140 mmHg or diastolic blood pressure !90 mmHg measured at the study visit, or the use of antihypertensive medication. BMI was calculated from measured weight and height. Total cholesterol, HDl cholesterol and triglycerides were measured by standardized enzymatic methods [24] and LDL cholesterol concentrations were then calculated. Serum albumin and hs-CRP were measured with the bromcresol purple method and an immunoturbidimetric assay, respectively. Smoking status was self-reported and dichotomized as current versus former/never.
Statistical analyses
Cross-sectional baseline characteristics of participants were compared using v 2 and t-tests for variables as appropriate. Associations with reduced kidney function were estimated using multivariable adjusted logistic regression models including age, gender, race, serum albumin, BMI, hs-CRP, smoking status, systolic blood pressure, diabetes, LDL and HDL cholesterol, triglycerides, hypertension, medication use for cholesterol and/or DM as well as either all thyroid function markers (each divided into quartiles) or euthyroidism/clinical categories of thyroid dysfunction as binary traits. Clinical categories of thyroid dysfunction included combined subclinical and overt hypothyroidism, combined subclinical and overt hyperthyroidism and TPOAb positivity for better comparability with other studies on hypo-/hyperthyroidism and to avoid small subgroups. Secondary analyses were carried out for subclinical and overt hypo-and hyperthyroidism separately as well as for models with reduced adjustment using the above-mentioned covariates devoid of LDL and HDL cholesterol, triglycerides hypertension and cholesterol-lowering medication use. Additional secondary analyses were carried out after exclusion of participants, who were started on any thyroid medication during follow-up (N ¼ 321).
The primary analyses focused on all ARIC participants (blacks and whites). Because there were racial differences in the distribution of thyroid hormone markers as well as the prevalence of some of the clinical categories of thyroid dysfunction (Supplementary data, Table S2 ), secondary analyses were carried out separately for blacks and whites.
We used Cox proportional hazards regression models to estimate hazard ratios of incident CKD as a function of TSH, FT4, T3 and TPOAb. All markers of thyroid function were included in each regression model, with concentrations examined in quartiles. Euthyroidism and clinical categories of thyroid dysfunction were included as binary traits in the regression models. Since previous studies have shown that thyroid dysfunction is a risk factor for cardiovascular death, we conducted a competing-risks analysis (CKD vs. death) to analyze the isolated effect of thyroid dysfunction on CKD. People with thyroid dysfunction may be more likely to die at a younger age before developing CKD which in turn may mask any significant findings in our study between thyroid dysfunction and CKD. Competing risk analyses were conducted using the Fine and Gray method [25] . Similar to Cox regression, time to event was from visit 2 to CKD or pre-CKD death, whichever came first, with censoring of participants who were event-free as of 31 December 2012. In addition to the above-mentioned covariates, analyses for prospective associations were adjusted for baseline eGFR. All analyses were conducted using Stata/SE 13 (StataCorp, College Station, TX, USA).
R E S U L T S
Population characteristics
Overall, 82% of the participants in our study population were euthyroid (Table 1) . Hypothyroidism was present in 6.5%, hyperthyroidism was detected in 4.9% and TPOAb positivity was identified in 13.7% of all participants. The mean eGFR was 96.4 mL/min/1.73 m 2 and 2% of all participants had reduced kidney function (eGFR <60 mL/min/1.73 m 2 ). Population characteristics in those with euthyroidism and for the different clinical categories of thyroid dysfunction can be found in Table 2 . The percentage of male participants was 26.1% for TPOAb positivity, 28.5% for hyperthyroidism, 30.2% for hypothyroidism and 45.5% for euthyroidism. The prevalence of clinical categories of thyroid dysfunction varied across races, with the proportion of whites being highest for hypothyroidism (88.2%) and lowest for hyperthyroidism (66.6%). The mean eGFR was highest, at 100.1 mL/min/1.73 m 2 , for hyperthyroidism and lowest, at 91.3 mL/min/1.73 m 2 , for hypothyroidism. The percentage of participants with reduced kidney function ranged from 1.4% for TPOAb positivity to 3.0% for hypothyroidism. The proportion of smokers was highest among participants with hyperthyroidism (28.5%) and lowest for participants with hypothyroidism (13.1%).
Cross-sectional association of reduced kidney function with thyroid markers Figure 1A (Q1, reference) . There was a significant inverse association between T3 and reduced kidney function ( Figure 1C) [OR 0.19 (95% CI 0.12-0.31), P < 0.001] for Q4 compared with Q1 (reference). No association was observed for TPOAb with reduced kidney function ( Figure 1D ). There was no statistically significant interaction between thyroid markers and race when evaluating their relationship with reduced kidney function. We therefore focused on the overall analyses.
Cross Table S3 ). The associations were also similar when analyses were adjusted for a reduced set of potential confounders, and can be found in Supplementary data, Table S4 . Race-specific associations of reduced kidney function with clinical categories of thyroid dysfunction are shown in Supplementary data, Table S5 . There were no statistically a significant associations for the race-specific analyses; case numbers for the two clinical categories of overt thyroid disease were too small and are therefore not shown. Secondary analyses explored the relationship between continuous eGFR and clinical categories of thyroid dysfunction. As summarized in Supplementary data, Table S6 , statistically significant associations were observed between eGFR and hypothyroidism as well as hyperthyroidism. The direction of the associations was consistent with those of the reduced kidney function analyses. Figure 2 shows the association of incident CKD with thyroid marker (TSH, FT4, T3, TPOAb) quartiles over a median followup time of 19.6 years among all ARIC participants. In models with limited adjustment (age, sex, race, hs-CRP, smoking, serum albumin and BMI), higher FT4 was significantly associated with incident CKD, but associations were much weaker than the cross-sectional association. Associations for TSH, T3 and TPOAb positivity were not significant. After adjustment for . p25/p50/p75, 25th, 50th and 75th percentiles. Table 4 displays the overall association of incident CKD with euthyroidism, hypothyroidism, hyperthyroidism and TPOAb positivity. None of the clinical categories of thyroid dysfunction showed a significant association with incident CKD after adjustment for potential confounders. The association for subclinical hypothyroidism with incident CKD was similar to the combined category of subclinical and overt hypothyroidism [hazard ratio (HR) 1.09 (95% CI 0.88-1.36), P ¼ 0.43]. These associations were generally similar in the secondary analyses incorporating participants taking thyroid medication at baseline (Supplementary data, Table S7 ) as well as for analyses that excluded participants who were started on thyroid medication during follow-up (data not shown). The associations were also similar for the reduced covariate adjustment (Supplementary data, Table S8 ). Taking death as a competing risk into account, the Fine and Gray competing-risks regression (Supplementary data, Table S9 ) showed subhazard ratios (SHRs) comparable with the main analysis from Cox proportional hazards regression in Table 4 . None of the race-specific associations of incident CKD with euthyroidism and clinical categories of thyroid dysfunction reached significance (Supplementary data, Table S10 ).
Association of incident CKD with measures of thyroid function and diseases
D I S C U S S I O N
In a large community-based black and white population, we detected a high prevalence of subclinical and overt thyroid dysfunction. Cross-sectionally, reduced kidney function was significantly associated with higher quartiles of TSH and FT4, lower quartiles of T3, as well as with having any clinical category of thyroid dysfunction compared with being euthyroid. However, these significant associations did not persist when evaluating incident CKD.
Our results on the prevalence of euthyroidism and clinical categories of thyroid dysfunction are in accordance with previously published data from National Health and Nutrition Examination Survey III, the Colorado thyroid disease prevalence study, the Health Study of Nord-Trondelag (HUNT) and others [15, 17, [26] [27] [28] [29] . Slight differences in numbers across the Comparison of all participants with a certain thyroid disorder (hypothyroidism/hyperthyroidism) with euthyroid participants. c Comparison of TPOAb-positive participants with TPOAb-negative participants.
Adjusted for age, gender, race, serum albumin, BMI, hs-CRP, smoking status, systolic blood pressure, diabetes, LDL and HDL cholesterol, triglycerides, hypertension and medication use for cholesterol and/or DM. OR, odds ratio; CI, confidence interval.
different studies can be due to a number of factors, including differences in study populations, age distribution, dietary iodine availability, assays used for the quantification of thyroid markers, thyroid marker reference ranges and thyroid disease definitions. Our findings of a multivariable adjusted cross-sectional association between thyroid function measures and kidney function are in agreement with other studies in the field: there are several cross-sectional, population-based, mostly European studies showing an inverse association between eGFR and serum TSH concentrations and an increased prevalence of hypothyroidism with incrementally impaired kidney function [12, 15, [30] [31] [32] [33] . The fact that these associations were observed for the middleaged population of the ARIC study suggests that higher TSH concentrations may not be a consequence of old age [15] , but of hypothyroidism itself.
So far, there has been little research on the association of a full panel of thyroid markers with reduced kidney function and incident CKD, and especially on T3, which has not been measured by many large population-based cohort studies. T3 was measured in the population-based HUNT study, but only for participants with low TSH concentrations. Moreover, analyses did not directly assess the association between T3 and reduced kidney function, and all analyses were restricted to evaluate cross-sectional associations [30] . Therefore, to the best of our knowledge, our study is the first large population-based study reporting an association between reduced kidney function and lower T3 concentrations.
Other novel aspects of this study are its separate analyses of white and black participants. There are known yet underrecognized racial differences in the distribution of thyroid function markers. Although effect modification of hypothyroidism and mortality by race has been observed [34] , very few studies have so far examined effect modification of the associations between thyroid function and outcomes by race. To the best of our knowledge, the ARIC study is the first study to examine effect modification of the association between thyroid function and CKD by race.
The prospective results from our study are consistent with previous findings on thyroid status and renal function in older persons of the general population [15] , where the association between thyroid status and change in renal function over time was also not significant. Results from the large populationbased Kangbuk Samsung Health Study showed a modest association of high-normal TSH and low-normal free T3 (FT3) concentrations with incident CKD [14] . However, this study differs from the ARIC study in several aspects: the study population consisted of a solely Asian population, the analyses only considered euthyroid participants and the above-mentioned association was only statistically significant after additionally accounting for time-varying effects in regression models. Several mechanisms may explain the cross-sectional link between thyroid hormones and renal function. Elevated TSH and hypothyroidism may worsen kidney function directly via reductions in cardiac output, increases in peripheral vascular resistance, intrarenal vasoconstriction and alterations in glomerular structure (e.g. decreased glomerular volume and area) [35, 36] . Moreover, thyroid hormones have important effects on renal tubular transport [37] [38] [39] , with a diminished tubular creatinine secretion in hypothyroidism leading to higher serum creatinine concentrations and a lower eGFR. The lack of prospective associations between thyroid dysfunction and incident CKD in the ARIC study suggests that abnormal thyroid function is not a cause of CKD. Under this assumption, a potential explanation for the statistically significant cross-sectional associations could be residual confounding by one or more of the above-mentioned mechanisms.
Although our study does not support thyroid disease as a risk factor for new-onset CKD, screening for thyroidal status and treatment to euthyroidism may be especially relevant in persons with reduced kidney function given the cross-sectional associations of thyroid markers and clinical categories of thyroid dysfunction with reduced kidney function as well as the high prevalence of thyroid dysfunction in the general population. Subclinical and overt hypothyroidism are associated with blood lipid alterations [7] , endothelial dysfunction [8] and atherosclerosis [9] leading to cardiovascular disease, which patients with reduced kidney function are already at risk for [40, 41] . Furthermore, there is evidence that thyroid hormone replacement therapy may lead to a significant improvement in renal function for patients with severe hypothyroidism [42, 43] . A recent cohort study showed that thyroid hormone therapy not only preserved renal function but also was an independent predictor of renal outcome in CKD patients with subclinical hypothyroidism, suggesting that thyroid hormone replacement should be considered in these patients [44] .
The strengths of our study include its large size, biracial composition and long duration of follow-up, as well as the availability of measurements of TSH, FT4, T3 and TPOAb and rigorous ascertainment of incident CKD events. Our study also has some limitations. We cannot exclude the possibility that the indirect assay used for the measurement of FT4 was less accurate in the setting of kidney disease, but only a small proportion of study participants had kidney disease, and especially advanced kidney disease, at the study baseline. Measurements of albuminuria to evaluate kidney damage were not available at the baseline visit for this study. The ARIC study investigators have carried out extensive calibration studies in order to account for inter-laboratory differences, measurement of creatinine from serum versus plasma, as well as drift over time [21] . Moreover, the endpoint definition of incident CKD included an eGFR decline from baseline of !25%, which together with the calibration reduces concern about the potential influence of differences in creatinine measurements over time. In addition, our results might not be representative for other populations with a different ethnic makeup or varying environmental exposures such as different levels of dietary iodine availability and smoking habits. Given the observational study design, we could not account for illness states resulting in secondary TSH fluctuations in the absence of thyroid pathology (nonthyroidal illness). Some participants who did not take thyroid medications at study baseline were started on thyroid medication during follow-up. Information about the starting date of medication was not available. We therefore cannot assess a potential effect of new thyroid medication intake over the course of our study on the risk of incident CKD. Finally, there may be residual confounding by factors affecting both thyroid and kidney function, such as chronic inflammation, that cannot be accounted for in this setting.
C O N C L U S I O N S
In summary, our study supports a cross-sectional association of elevated TSH and FT4 and lower T3 with reduced kidney function. We did not find a prospective association between any of these measures and incident CKD, suggesting that thyroid dysfunction is not a cause of CKD in the general population. Because of the observed cross-sectional associations of thyroid markers with reduced kidney function and the high prevalence of thyroid dysfunction in the general population, screening for thyroid status and treatment to euthyroidism may be especially relevant in persons with reduced kidney function. 
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